Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant and Ubrogepant PK in Lactation
NCT05892757Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atogepant in migraine (2 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events at Day 30, Maximum Observed Plasma Concentration (Cmax) at Day 2 and 5 more. Started Jul 2023; status: completed.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05892757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05892757.